This differs from the typical use of asparaginase-based products in other hematologic malignancies, which is typically limited to children, adolescents, and young adults (age <40 years old), given the decreased tolerability of the toxicities associated with asparaginase and related products in older patients. Here, ASPG is linked to hematologic disorder.